Citius Pharmaceuticals (CTXR)

Executive Summary

Citius Pharmaceuticals (Nasdaq: CTXR) is a late-stage biopharmaceutical company developing first-in-class critical care products, focusing on anti-infectives, oncology, adjunct cancer care, and stem cell therapy. The company's lead candidate, CITI-002, has completed Phase 2 trials for hemorrhoids, showing promising results. Citius also has an approved product portfolio, though details are limited. With a market valuation of approximately $19.3 million, the company is positioned to advance its pipeline toward commercialization. Recent strategic initiatives suggest a focus on regulatory filings and partnership opportunities to maximize the value of its core assets.

Upcoming Catalysts (preview)

• Q1 2025Initiation of Phase 3 Trial for CITI-002 in Hemorrhoids60% success
• Q4 2024FDA Meeting or Guidance for CITI-002 Development Path70% success
• Q2 2025Potential Licensing or Partnership Deal for Mino-Lok or Other Pipeline Assets50% success